Cargando…

The seroprevalence of untreated chronic hepatitis C virus (HCV) infection and associated risk factors in male Irish prisoners: a cross-sectional study, 2017

INTRODUCTION: Data on chronic hepatitis C (HCV) infection prevalence in European prisons are incomplete and impact the public health opportunity that incarceration provides. AIMS: We aimed to estimate the seroprevalence of untreated chronic HCV infection and to identify associated risk factors in an...

Descripción completa

Detalles Bibliográficos
Autores principales: Crowley, Desmond, Lambert, John S, Betts-Symonds, Graham, Cullen, Walter, Keevans, Mary, Kelly, Enda, Laird, Eamon, McHugh, Tina, McKiernan, Susan, Miggin, Sarah Jayne, Murphy, Carol, Murtagh, Ross, O'Reilly, Deirdre, Tobin, Ciara, Van Hout, Marie Claire
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Centre for Disease Prevention and Control (ECDC) 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6462789/
https://www.ncbi.nlm.nih.gov/pubmed/30968825
http://dx.doi.org/10.2807/1560-7917.ES.2019.24.14.1800369
_version_ 1783410640824565760
author Crowley, Desmond
Lambert, John S
Betts-Symonds, Graham
Cullen, Walter
Keevans, Mary
Kelly, Enda
Laird, Eamon
McHugh, Tina
McKiernan, Susan
Miggin, Sarah Jayne
Murphy, Carol
Murtagh, Ross
O'Reilly, Deirdre
Tobin, Ciara
Van Hout, Marie Claire
author_facet Crowley, Desmond
Lambert, John S
Betts-Symonds, Graham
Cullen, Walter
Keevans, Mary
Kelly, Enda
Laird, Eamon
McHugh, Tina
McKiernan, Susan
Miggin, Sarah Jayne
Murphy, Carol
Murtagh, Ross
O'Reilly, Deirdre
Tobin, Ciara
Van Hout, Marie Claire
author_sort Crowley, Desmond
collection PubMed
description INTRODUCTION: Data on chronic hepatitis C (HCV) infection prevalence in European prisons are incomplete and impact the public health opportunity that incarceration provides. AIMS: We aimed to estimate the seroprevalence of untreated chronic HCV infection and to identify associated risk factors in an Irish male prison. METHODS: We conducted a cross-sectional study involving a researcher-administered questionnaire, review of medical records and HCV serology. RESULTS: Of 422 prisoners (78.0% of the study population) who participated in the study, 298 (70.6%) completed the questionnaire and 403 (95.5%) were tested for HCV antibodies. Of those tested, 92 (22.8%) were HCV antibody-positive, and of those, 53 (57.6%) were HCV RNA-positive, 23 (25.0%) had spontaneous clearance, 16 (17.4%) had a sustained viral response, 10 (11.0%) were co-infected with HIV and six (6.0%) with HBV. The untreated chronic HCV seroprevalence estimate was 13.1% and the seroprevalence of HCV among prisoners with a history of injecting drug use (IDU) was 79.7%. Risk factors significantly associated with past HCV infection were IDU (p < 0.0001), having received a prison tattoo (p < 0.0001) or a non-sterile community tattoo (p < 0.0001), sharing needles and other drug-taking paraphernalia (p < 0.0001). Small numbers of prisoners had a history of sharing razors (n=10; 3.4%) and toothbrushes (n=3; 1.0%) while incarcerated. On multivariable analysis, history of receiving a non-sterile community tattoo was the only significant risk factor associated with HCV acquisition (after IDU was removed from the model) (p = 0.005, β = 0.468). CONCLUSION: The level of untreated chronic HCV infection in Irish prisons is high, with IDU the main associated risk.
format Online
Article
Text
id pubmed-6462789
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher European Centre for Disease Prevention and Control (ECDC)
record_format MEDLINE/PubMed
spelling pubmed-64627892019-04-24 The seroprevalence of untreated chronic hepatitis C virus (HCV) infection and associated risk factors in male Irish prisoners: a cross-sectional study, 2017 Crowley, Desmond Lambert, John S Betts-Symonds, Graham Cullen, Walter Keevans, Mary Kelly, Enda Laird, Eamon McHugh, Tina McKiernan, Susan Miggin, Sarah Jayne Murphy, Carol Murtagh, Ross O'Reilly, Deirdre Tobin, Ciara Van Hout, Marie Claire Euro Surveill Research INTRODUCTION: Data on chronic hepatitis C (HCV) infection prevalence in European prisons are incomplete and impact the public health opportunity that incarceration provides. AIMS: We aimed to estimate the seroprevalence of untreated chronic HCV infection and to identify associated risk factors in an Irish male prison. METHODS: We conducted a cross-sectional study involving a researcher-administered questionnaire, review of medical records and HCV serology. RESULTS: Of 422 prisoners (78.0% of the study population) who participated in the study, 298 (70.6%) completed the questionnaire and 403 (95.5%) were tested for HCV antibodies. Of those tested, 92 (22.8%) were HCV antibody-positive, and of those, 53 (57.6%) were HCV RNA-positive, 23 (25.0%) had spontaneous clearance, 16 (17.4%) had a sustained viral response, 10 (11.0%) were co-infected with HIV and six (6.0%) with HBV. The untreated chronic HCV seroprevalence estimate was 13.1% and the seroprevalence of HCV among prisoners with a history of injecting drug use (IDU) was 79.7%. Risk factors significantly associated with past HCV infection were IDU (p < 0.0001), having received a prison tattoo (p < 0.0001) or a non-sterile community tattoo (p < 0.0001), sharing needles and other drug-taking paraphernalia (p < 0.0001). Small numbers of prisoners had a history of sharing razors (n=10; 3.4%) and toothbrushes (n=3; 1.0%) while incarcerated. On multivariable analysis, history of receiving a non-sterile community tattoo was the only significant risk factor associated with HCV acquisition (after IDU was removed from the model) (p = 0.005, β = 0.468). CONCLUSION: The level of untreated chronic HCV infection in Irish prisons is high, with IDU the main associated risk. European Centre for Disease Prevention and Control (ECDC) 2019-04-04 /pmc/articles/PMC6462789/ /pubmed/30968825 http://dx.doi.org/10.2807/1560-7917.ES.2019.24.14.1800369 Text en This article is copyright of the authors or their affiliated institutions, 2019. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.
spellingShingle Research
Crowley, Desmond
Lambert, John S
Betts-Symonds, Graham
Cullen, Walter
Keevans, Mary
Kelly, Enda
Laird, Eamon
McHugh, Tina
McKiernan, Susan
Miggin, Sarah Jayne
Murphy, Carol
Murtagh, Ross
O'Reilly, Deirdre
Tobin, Ciara
Van Hout, Marie Claire
The seroprevalence of untreated chronic hepatitis C virus (HCV) infection and associated risk factors in male Irish prisoners: a cross-sectional study, 2017
title The seroprevalence of untreated chronic hepatitis C virus (HCV) infection and associated risk factors in male Irish prisoners: a cross-sectional study, 2017
title_full The seroprevalence of untreated chronic hepatitis C virus (HCV) infection and associated risk factors in male Irish prisoners: a cross-sectional study, 2017
title_fullStr The seroprevalence of untreated chronic hepatitis C virus (HCV) infection and associated risk factors in male Irish prisoners: a cross-sectional study, 2017
title_full_unstemmed The seroprevalence of untreated chronic hepatitis C virus (HCV) infection and associated risk factors in male Irish prisoners: a cross-sectional study, 2017
title_short The seroprevalence of untreated chronic hepatitis C virus (HCV) infection and associated risk factors in male Irish prisoners: a cross-sectional study, 2017
title_sort seroprevalence of untreated chronic hepatitis c virus (hcv) infection and associated risk factors in male irish prisoners: a cross-sectional study, 2017
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6462789/
https://www.ncbi.nlm.nih.gov/pubmed/30968825
http://dx.doi.org/10.2807/1560-7917.ES.2019.24.14.1800369
work_keys_str_mv AT crowleydesmond theseroprevalenceofuntreatedchronichepatitiscvirushcvinfectionandassociatedriskfactorsinmaleirishprisonersacrosssectionalstudy2017
AT lambertjohns theseroprevalenceofuntreatedchronichepatitiscvirushcvinfectionandassociatedriskfactorsinmaleirishprisonersacrosssectionalstudy2017
AT bettssymondsgraham theseroprevalenceofuntreatedchronichepatitiscvirushcvinfectionandassociatedriskfactorsinmaleirishprisonersacrosssectionalstudy2017
AT cullenwalter theseroprevalenceofuntreatedchronichepatitiscvirushcvinfectionandassociatedriskfactorsinmaleirishprisonersacrosssectionalstudy2017
AT keevansmary theseroprevalenceofuntreatedchronichepatitiscvirushcvinfectionandassociatedriskfactorsinmaleirishprisonersacrosssectionalstudy2017
AT kellyenda theseroprevalenceofuntreatedchronichepatitiscvirushcvinfectionandassociatedriskfactorsinmaleirishprisonersacrosssectionalstudy2017
AT lairdeamon theseroprevalenceofuntreatedchronichepatitiscvirushcvinfectionandassociatedriskfactorsinmaleirishprisonersacrosssectionalstudy2017
AT mchughtina theseroprevalenceofuntreatedchronichepatitiscvirushcvinfectionandassociatedriskfactorsinmaleirishprisonersacrosssectionalstudy2017
AT mckiernansusan theseroprevalenceofuntreatedchronichepatitiscvirushcvinfectionandassociatedriskfactorsinmaleirishprisonersacrosssectionalstudy2017
AT migginsarahjayne theseroprevalenceofuntreatedchronichepatitiscvirushcvinfectionandassociatedriskfactorsinmaleirishprisonersacrosssectionalstudy2017
AT murphycarol theseroprevalenceofuntreatedchronichepatitiscvirushcvinfectionandassociatedriskfactorsinmaleirishprisonersacrosssectionalstudy2017
AT murtaghross theseroprevalenceofuntreatedchronichepatitiscvirushcvinfectionandassociatedriskfactorsinmaleirishprisonersacrosssectionalstudy2017
AT oreillydeirdre theseroprevalenceofuntreatedchronichepatitiscvirushcvinfectionandassociatedriskfactorsinmaleirishprisonersacrosssectionalstudy2017
AT tobinciara theseroprevalenceofuntreatedchronichepatitiscvirushcvinfectionandassociatedriskfactorsinmaleirishprisonersacrosssectionalstudy2017
AT vanhoutmarieclaire theseroprevalenceofuntreatedchronichepatitiscvirushcvinfectionandassociatedriskfactorsinmaleirishprisonersacrosssectionalstudy2017
AT crowleydesmond seroprevalenceofuntreatedchronichepatitiscvirushcvinfectionandassociatedriskfactorsinmaleirishprisonersacrosssectionalstudy2017
AT lambertjohns seroprevalenceofuntreatedchronichepatitiscvirushcvinfectionandassociatedriskfactorsinmaleirishprisonersacrosssectionalstudy2017
AT bettssymondsgraham seroprevalenceofuntreatedchronichepatitiscvirushcvinfectionandassociatedriskfactorsinmaleirishprisonersacrosssectionalstudy2017
AT cullenwalter seroprevalenceofuntreatedchronichepatitiscvirushcvinfectionandassociatedriskfactorsinmaleirishprisonersacrosssectionalstudy2017
AT keevansmary seroprevalenceofuntreatedchronichepatitiscvirushcvinfectionandassociatedriskfactorsinmaleirishprisonersacrosssectionalstudy2017
AT kellyenda seroprevalenceofuntreatedchronichepatitiscvirushcvinfectionandassociatedriskfactorsinmaleirishprisonersacrosssectionalstudy2017
AT lairdeamon seroprevalenceofuntreatedchronichepatitiscvirushcvinfectionandassociatedriskfactorsinmaleirishprisonersacrosssectionalstudy2017
AT mchughtina seroprevalenceofuntreatedchronichepatitiscvirushcvinfectionandassociatedriskfactorsinmaleirishprisonersacrosssectionalstudy2017
AT mckiernansusan seroprevalenceofuntreatedchronichepatitiscvirushcvinfectionandassociatedriskfactorsinmaleirishprisonersacrosssectionalstudy2017
AT migginsarahjayne seroprevalenceofuntreatedchronichepatitiscvirushcvinfectionandassociatedriskfactorsinmaleirishprisonersacrosssectionalstudy2017
AT murphycarol seroprevalenceofuntreatedchronichepatitiscvirushcvinfectionandassociatedriskfactorsinmaleirishprisonersacrosssectionalstudy2017
AT murtaghross seroprevalenceofuntreatedchronichepatitiscvirushcvinfectionandassociatedriskfactorsinmaleirishprisonersacrosssectionalstudy2017
AT oreillydeirdre seroprevalenceofuntreatedchronichepatitiscvirushcvinfectionandassociatedriskfactorsinmaleirishprisonersacrosssectionalstudy2017
AT tobinciara seroprevalenceofuntreatedchronichepatitiscvirushcvinfectionandassociatedriskfactorsinmaleirishprisonersacrosssectionalstudy2017
AT vanhoutmarieclaire seroprevalenceofuntreatedchronichepatitiscvirushcvinfectionandassociatedriskfactorsinmaleirishprisonersacrosssectionalstudy2017